Pernix Therapeutics to buy Great Southern Laboratories
The assets under certain liabilities include Great Southern’s buildings and land located in Houston, Texas, US. The acquisition will enable Pernix to improve the company’s gross margins on
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Under the collaboration, Cellworks will leverage its proprietary predictive platform to model drug MDR-TB and rationally identify synergistic combinations with highest possible efficacy and lowest possible toxic burden